Related Experiment Videos

[Angiogenesis as a prognostic factor of breast cancers]

K Kuroi¹, M Toi

¹Department of Surgery, Tokyo Metropolitan Komagome Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|October 12, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

ESMO open·2024

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

ESMO open·2024

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

See all related articles